MorphoSys AG : Results from MANIFEST-2 II study are good BUT might not be good enough
>Strong results for the primary endpoint - secondary endpoints good, but not statistically significant - Yesterday evening, Morphosys published the key results of the long-awaited MANIFEST-2 study of its potential blockbuster drug pelabresib (expected peak sales of approximately € 1.54bn) in myelofibrosis. The results of the study showed a strong primary endpoint, namely an almost doubled SVR35 (spleen volume reduction of 35%) response rate of 66% vs 35%. The key seco...MorphoSys is engaged in development and commercialization of antibodies for therapeutic applications. Co. operates in two segments: Partnered Discovery, which operates therapeutic development programs for drug candidates in cooperation with biotechnology and pharmaceutical companies; and Proprietary Development, which is engaged in the development of therapeutic antibodies in the area of inflammatory disease and oncology on a proprietary basis. As of Dec 31 2013, Co.'s proprietary antibody compounds in clinical trials included MOR103 in the areas of rheumatoid arthritis and multiple sclerosis; MOR202 in the field of multiple myeloma; and MOR208 in the field of malignant B-cell diseases.
Oddo Securities provides securities brokerage and research services. The company offers equity, economic, and derivatives research and credit analysis services. It focuses on insurance, automotive, building materials, pharmaceuticals, telecommunications, information technology, and agri-food industries.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.